Comparison of conventional ELISA with electrochemiluminescence technology for detection of amyloid-β in plasma.

Journal of Alzheimer's Disease : JAD
Esther S OhPankaj D Mehta

Abstract

Plasma amyloid-β (Aβ) level could be useful as a non-invasive biomarker in Alzheimer's disease research. We compared a multiplex electrochemiluminescence detection method with a well established ELISA method for plasma Aβ quantification. Compared to the ELISA method, the electrochemiluminescence detection method demonstrates a statistically significant, but modest correlation. The reasons for this may include the differences in the affinities of antibodies, and purity and source of Aβ peptides used as standards. However, the advantages of electrochemiluminescence detection technology include short processing time and small sample volume. This comparison demonstrates the need for a further study in optimizing this system.

Citations

Nov 22, 2017·Molecular Neurodegeneration·Ebru ErcanDagmar E Ehrnhoefer
Nov 2, 2016·Lab on a Chip·Matthew Y H Tang, Ho Cheung Shum
Apr 28, 2012·International Journal of Geriatric Psychiatry·Daniel C ParkerEsther S Oh
Mar 1, 2015·Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring·Melissa EdwardsSid O'Bryant
Mar 30, 2019·Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring·Sid E O'BryantNeill R Graff-Radford
Sep 29, 2015·Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring·Esther S OhConstantine G Lyketsos
Oct 30, 2019·Critical Reviews in Clinical Laboratory Sciences·Bhavana VeerabhadrappaSylvain Lehmann
Dec 25, 2013·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Heather M SnyderHoward M Fillit
Jul 7, 2020·Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring·Melissa E PetersenUNKNOWN Alzheimer's Biomarker Consortium – Down Syndrome (ABC‐DS)
Jun 4, 2020·Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring·Sid E O'BryantNicole Schupf
Sep 29, 2020·Frontiers in Aging Neuroscience·Christiana BjorkliIoanna Sandvig
Oct 8, 2015·Journal of Alzheimer's Disease : JAD·Melissa EdwardsSid O'Bryant
May 22, 2020·Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring·Melissa PetersenSid E O'Bryant
Dec 1, 2020·Journal of Alzheimer's Disease : JAD·Pankaj D MehtaThomas Wisniewski
Jun 17, 2020·British Journal of Anaesthesia·Stacie DeinerRoderic Eckenhoff
Aug 14, 2020·Dementia and Geriatric Cognitive Disorders·Jui-Feng ChangShieh-Yueh Yang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.